Advertisement
Advertisement

IMUX

IMUX logo

Immunic, Inc. Common Stock

14.79
USD
Sponsored
+0.08
+0.55%
Jun 25, 13:44 UTC -4
Open

IMUX Earnings Reports

Positive Surprise Ratio

IMUX beat 2 of 3 last estimates.

67%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$1.19
Implied change from Q1 26 (Revenue/ EPS)
--
/
+10.19%
Implied change from Q2 25 (Revenue/ EPS)
--
/
-40.50%

Immunic, Inc. Common Stock earnings per share and revenue

On May 13, 2026, IMUX reported earnings of -1.08 USD per share (EPS) for Q1 26, missing the estimate of -0.93 USD, resulting in a -16.03% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +8.82% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -1.19 USD, with revenue projected to reach -- USD, implying an increase of 10.19% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Grace Therapeutics, Inc. Common Stock
Report Date
Jun 18, 2026 For Q4 26
Estimate
-$0.23
Actual
-$0.06
Surprise
+74.42%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, Immunic, Inc. Common Stock reported EPS of -$1.08, missing estimates by -16.03%, and revenue of $0.00, 0% as expectations.
The stock price moved up 8.82%, changed from $11.90 before the earnings release to $12.95 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on -- analysts, Immunic, Inc. Common Stock is expected to report EPS of -$1.19 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement